Giotrif beats Iressa in EGFR mutation-positive advanced NSCLC, new study shows

Results from LUX-Lung 7, a global head-to-head Phase IIb trial comparing treatment with Boehringer Ingelheim’s Giotrif(afatinib) to AstraZeneca’s Iressa (gefitinib) in patients whose tumors harbor the most common EGFR mutations were published in The Lancet Oncology, showing afatinib significantly reduced the risk of lung cancer progression and treatment failure

LUX-Lung 7 lead investigator and lead author Professor Keunchil Park, director of Innovative Cancer Medicine Institute (ICMI) at Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, commented: “The key finding from this study suggests a significant difference in efficacy between afatinib and gefitinib across multiple endpoints and pre-defined patient subgroups.”

Reduced risk of lung cancer progression by 27%